AngioDynamics Inc (ANGO)
6.10
-0.27
(-4.24%)
USD |
NASDAQ |
Oct 04, 16:00
6.10
0.00 (0.00%)
After-Hours: 20:00
AngioDynamics SG&A Expense (Annual): 143.98M for May 31, 2024
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
May 31, 2024 | 143.98M |
May 31, 2023 | 144.25M |
May 31, 2022 | 133.75M |
May 31, 2021 | 117.22M |
May 31, 2020 | 116.51M |
May 31, 2019 | 111.73M |
May 31, 2018 | 104.10M |
May 31, 2017 | 106.00M |
May 31, 2016 | 114.33M |
May 31, 2015 | 112.38M |
May 31, 2014 | 112.21M |
May 31, 2013 | 102.31M |
Date | Value |
---|---|
May 31, 2012 | 83.54M |
May 31, 2011 | 75.95M |
May 31, 2010 | 77.36M |
May 31, 2009 | 76.92M |
May 31, 2008 | 61.47M |
May 31, 2007 | 56.84M |
May 31, 2006 | 29.35M |
May 31, 2005 | 21.08M |
May 31, 2004 | 17.13M |
May 31, 2003 | 14.12M |
May 31, 2002 | 11.22M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
116.51M
Minimum
2020
144.25M
Maximum
2023
131.14M
Average
133.75M
Median
2022
SG&A Expense (Annual) Benchmarks
Accuray Inc | 92.68M |
Boston Scientific Corp | 5.19B |
Masimo Corp | 664.00M |
Globus Medical Inc | 643.41M |
Perspective Therapeutics Inc | 21.06M |